Novel developments on immunocytokines
Antibody-cytokine fusions (also called “immunocytokines”) are a new class of biopharmaceuticals, which are being considered for the therapy of cancer and of other serious conditions [Neri (2019) Cancer Immunol. Res., 7, 348]. When designing immunocytokine products, a number of parameters have to be considered, including the choice of antigen and the format for the antibody-cytokine fusion.
In this lecture, I will review antibody-cytokine fusions which have been developed at Philogen [www.philogen.com] and which are being investigated in clinical trials in patients with cancer. Specifically, I will focus on immunocytokines based on interleukin-2, interleukin-12 and tumor necrosis factor as payloads. The tumor targeting properties, as well as emerging preclinical and clinical findings, will be discussed.